Fundamental Role of Neurochemicals Aberration in the Pathogenesis of Autism Spectrum Disorders by Meguid, Nagwa A. et al.
Open Access Maced J Med Sci. 2020 Aug 25; 8(B):921-929. 921
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2020 Aug 25; 8(B):921-929.
https://doi.org/10.3889/oamjms.2020.5268
eISSN: 1857-9655
Category: B - Clinical Sciences
Section: Neurology
Fundamental Role of Neurochemicals Aberration in the 
Pathogenesis of Autism Spectrum Disorders
Nagwa A. Meguid1, Hanaa H. Ahmed2*, Manal A. Gad3, Olwaya M. Abdel Baki3, Samia S. Aziz3, Emad F. Eskander2
¹Department of Research on Children with Special Needs, National Research Centre, Dokki, Giza, Egypt; ²Department of 
Hormones, National Research Centre, Dokki, Giza, Egypt; ³Department of Medical Studies, Faculty of Graduate Studies for 
Childhood, Ain Shams University, Cairo, Egypt
Abstract
AIM: The aim of this research was to establish the perturbation of reliable biomarkers implicated in the pathophysiology 
of autism to help in the early diagnosis and to be as targets in the treatment of autism spectrum disorders (ASDs) in 
children and to spotlight into the complex crosstalk between these biomarkers.
PATIENS AND METHODS: This study included 90 autistic children aged from 2 to 7 years old, who were classified 
into two groups, the atypical autism of 30 children and the childhood autism. The childhood autism group was further 
divided into mild-moderate autism group and severe autism group each of 30 children. The control group included 
30 matched healthy children. All the participants were subjected to full psychiatric examinations, psychological 
investigations, and biochemical measurements, including gamma-aminobutaric acid (GABA), serotonin, dopamine 
(DA) in plasma, and brain-derived neurotrophic factor (BDNF) in serum.
RESULTS: The autistic groups showed a highly significant increase in GABA, serotonin, DA, and BDNF levels 
compared to the control. Of note, the levels of GABA, DA, and BDNF were significantly increased with the increased 
disease severity. Furthermore, a significant positive correlation between BDNF levels and both GABA and DA levels 
in the childhood autism group has been recorded.
CONCLUSION: The present clinical setting provides new insight into the fundamental role of BDNF in the brain of 
autistic children as any alterations of its level due to GABA increment cause change in serotonin and DA levels which 
have empirical evidence in the pathophysiology of ASD. The results received in this research, create a fertile base 
for the setup of particular targets in the intervention of this ailment.
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Introduction
The Diagnostic and Statistical Manual of 
Mental Disorders, 5th Revision (DSM-V) describes 
autism spectrum disorder (ASD) as a neurological 
disorder with a spectrum of qualitative impairments 
in social interaction and in communication as well as 
restricted stereotyped patterns of behavior, activities, 
and interests. Autism is growing faster than any other 
special needs disorders worldwide. The rate of ASD 
has increased dramatically in the globe by 600% in 
the past few decades [1]. The most widely published 
male-female ratio of autism incidence is 4–5:1, lower 
in people with intellectual disability and higher at the 
high functioning end. Interestingly, a higher percentage 
of females have coincident intellectual disabilities [2].
The rational for dismissing peripheral influences 
on the brain due to the belief that the brain is protected 
from the events that impinge on the peripheral organs 
which is being increasingly undermined. The blood 
brain barrier does not mature until significantly after 
birth, and its permeability is drastically modulated even 
in adulthood by factors such as fever and circulating 
cytokines [3]. As well as, multiple stressors as hypoxia, 
ammonia, and endotoxin have been confirmed to cause 
the opening up of tight junctions in the BBB, permitting 
not only pathogens but also small molecules infiltrate 
the barrier causes a remarkable increase in membrane 
permeability in the BBB [4]. Other definite regions of the 
brain identified as the circumventricular organs fail to 
develop BBB, so they are potential gates for toxicants 
if not close of by BBB after 1 year [5]. Furthermore, 
in humans, about 500 ml of CSF is absorbed into 
blood daily, making blood appropriate source of 
neurodegenerative disease biomarkers [6].
Alterations in the neurotransmitters during brain 
development involve serotonergic and dopaminergic 
systems which are proposed to be contributed to 
the pathophysiology of ASD [7]. Researchers have 
mainly concentrated on mapping biomarkers onto 
clinically distinct categories, but such categories do 
not catch the present understanding of the increasingly 
multidimensional and complex clinical, cognitive, and 
behavioral phenotype that is connected with autism and 
its overlap with other disorders [8]. Serotonin, for many 
years, has been hypothesized that it plays an important 
role in the pathogenesis of autism. The first support 
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that serotonin may have a role in autism derived from 
studies that measure blood level of serotonin from 
patients with autism, which found that blood and serum 
serotonin levels are increased even though these 
effects differed by age and ethnicity [9]. Dopamine (DA) 
acts as an essential neurotransmitter in the brain; the 
dopaminergic effect is mostly exerted over the frontal 
lobe and basal ganglia. It has been stated that cognitive 
deficits express changes in these subcortical brain 
structures with modification of executive functions. 
These observations propose a role for DA in regulating 
cognitive functions. A study of Kohls et al. [10] mentioned 
that individuals with ASD exhibit a reduced response 
to reward, which derives from striatal dysfunction. 
ASD is connected with variants in several genes of 
DA network, as well as those encoding STX1, the DA 
transporter, DA receptors, and enzymes involved in DA 
metabolism [11]. Gamma-aminobutaric acid (GABA) 
represents only 10–15% of all neuronal populations. 
Yet, they supply the functional balance, complexity, 
and computational architecture of neuronal circuits. 
Adding to its function as an inhibitory neurotransmitter, 
GABA is as well implicated in neural maturity and circuit 
development. The GABA neurotransmitter structure 
has as well been involved in the pathophysiology of 
ASD, throughout genetic connections with areas coding 
for GABA-A receptor subunits in families with ASD [12]. 
A numeral of researches noted different outcomes 
concerning brain-derived neurotrophic factor (BDNF) 
values in the serum or brains of autistic individuals. The 
BDNF levels have been noted to be 3 times as elevated 
as a control in the basal forebrain of ASD patients [13].
Accordingly, the goals of this work were to 
justify the aberration of the relevant neurochemical 
markers contributed in the pathogenesis of ASD and 
to explore the key actors in this pathologic ailment to 
facilitate early diagnosis and establishment of targeted 
therapeutic strategy.
Patients and Methods
Patients
The current study was carried out on 90 children 
diagnosed as childhood autism and atypical autism 
(case groups) according to the World Health ICD-10 
criteria. The study included 66 males and 24 females 
aged from 2–7 years old. All the diagnosed children 
frequently attended the outpatient Clinic of Center for 
Care of Children with Special Needs; Faculty of Post 
Graduate Studies for Childhood, Ain Shams University, 
Cairo, Egypt, during the period from January 2014 to 
January 2015. The atypical autism group consisted of 
30 children and the childhood autism group consisted 
of 60 children. The childhood autism group was further 
classified into two groups according to the severity of 
the disorder measured by Childhood Autism Rating 
Scale (CARS), mild-moderate autism group and severe 
autism group; each group consisted of 30 children. The 
study also included 30 healthy children (15 males and 
15 females) as a control group, they were age and sex 
matched and they were healthy schoolchildren from 
Cairo, Egypt. Depending on Correia et al. [14] who 
found that Mean ± SD of the BDNF in µg/L in autistic and 
control children are 40.44 ± 13.87 and 23.26 ± 12.34, 
respectively, and by considering the power = 0.80 and 
α = 0.05 as well as when using PASS 11th, the minimal 
sample size for an equal size study is released to be 11 
in each group [15]. Therefore, we recruited 30 in each 
group for possible other comparisons.
Inclusion criteria
The following criteria were included in the 
study:
•	 Age from 2 to 7 years.
•	 Male and female children.
•	 Medication free for at least 1 month before 
inclusion in the study.
Exclusion criteria
The following criteria were excluded from the 
study:
•	 Children with autistic feature syndromes as 
Down syndrome.
•	 Children with Rett disorder.
•	 Children with Asperser’s disorder.
•	 Children with childhood disintegrative disorder.
•	 Children with cerebral palsy.
•	 Children with central nervous system (CNS) 
diseases.
•	 Children with sensory impairments.
•	 Children with epilepsy in association with 
autoimmune diseases or any inflammatory 
conditions.
This study was approved by the “Ethical 
Committee” of National Research Centre, Giza, Egypt, 
and the written informed consent was obtained from 
the parents of the studied patients after explanation 
of the aim of the study and its possible benefits on 
their children and other children who have the same 
conditions (Ethical approval numbers: 11023).
Methods
All the children included in the study (patients 
and controls) were subjected to the following: 
Full psychiatric history and complete psychiatric 
examination. Each child was submitted to full medical 
history and clinical examination with particular 
emphasis on complete neurological examination, and 
any immune activation such as elevated temperature, 
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infections, or inflammatory diseases. Furthermore, 
EEG with full neurological history was done to exclude 
the presence of epilepsy in the subjects included in 
this study. Psychological assessment was performed 
to confirm the diagnoses of both childhood autism and 
atypical autism and to detect the severity of the disease 
using the CARS Second Edition. It is subjectively 
rated 15 items; relating to people, imitation, emotional 
response, body use, object use, adaptation to change, 
visual response, listening response, taste-smell-touch 
response and use, fear and nervousness, verbal 
communication, non-verbal communication, activity 
level, level of consistency of intellectual response, 
and general impressions. The second edition of CARS 
expands the test’s clinical value, making it more 
responsive to individuals on the “high functioning” end 
of autism spectrum disorders. The clinician rates the 
individual on each item, using a 4-point rating scale. 
Ratings are based on frequency of the behavior in 
question, its intensity, peculiarity, and duration [16]. 
The scores of our patients and control groups are 
estimated and then categorized in severity according to 
CARS scores into non-autistic with scores <25, autistic 
features with scores 25–29, mild-moderate autism with 
scores 30–36, and severe autism with scores 37–60. 
Vineland Adaptive Behavior Scale (VABS) Second 
Edition was applied to measure the personal and social 
skills since birth, diagnosing and classifying mental 
retardation, and autistic disorder. It assesses adaptive 
behavior in four domains: Communication, daily living 
skills, socialization, and motor skills. It also provides 
a composite score that summarizes the individual’s 
performance across all four domains [17]. The scores 
of our patients and control children are estimated 
and their social intelligent quotient (IQ) was detected 
according to the Vineland IQ scores which are divided 
into borderline IQ with scores 80–71, mild deficient IQ 
with scores 70–51, moderate deficient IQ with scores 
50–35, severe deficient IQ with scores 34–20, and 
profound deficient IQ with score <20. The low average 
IQ was estimated with scores 80–90, the average IQ 
with scores 90–100, the above average IQ with scores 
100–110, and the superior IQ with scores above 110.
Biochemical markers
From all the fasting children (autistic groups 
and the control group), 5 ml of blood sample was 
withdrawn from each child by venous arm puncture 
and partitioned into two tubes; a plain tube left to clot 
at room temperature for separation of serum and a 
heparinized tube for separation of platelet-rich plasma. 
Both the serum and the platelet-rich plasma were 
separated by centrifugation at 1800× g under cooling 
(4°C) for 15 min. GABA plasma level was estimated 
using an enzyme-linked immunosorbent assay 
(ELISA) kit (Glory Science Co., Ltd., USA) according 
to the manufacturer’s protocol. BDNF serum level 
was measured using an ELISA kit (Glory Science Co., 
Ltd., USA) according to the manufacturer’s procedure. 
Serotonin (5HT) plasma level was measured using an 
ELISA kit (Glory Science Co., Ltd., USA) according to 
the manufacturer’s instructions. DA plasma level was 
measured using an ELISA kit (Glory Science Co., Ltd., 
USA) according to the manufacturer’s manual.
Statistical analysis
Statistical analysis was performed using the 
SPSS statistical package software for Windows version 
20 (SPSS Inc., Chicago, Illinois, USA). Parametric 
variables among the controls and the studied patient 
groups were analyzed using two-tailed unpaired t-test; 
the t-value measures the size of the difference relative 
to the variation in your sample data, T is simply the 
calculated difference represented in units of standard 
error.
t(βl) = ((βl)−β0)/s.e(βl) 
Where, β0 is a non-random, known constant 
which may or may not match the actual unknown 
parameter value β, and s.e (β l) is the standard error of 
the estimator (β l) for β.
Qualitative variables were assessed by the 
Chi-square test. p < 0.05 (degree of freedom, df = 95%) 
was considered significant difference and p < 0.01 
(degree of freedom, df = 99%) was considered highly 
significant difference. Pearson’s correlation coefficient 
r measures the strength and direction of a linear 
relationship between two variables on a scatter plot. 
The value of r is always between +1 and –1.
Results
This study included 90 male and female autistic 
children (73.3% of males and 26.7% of females). The 
data in Table 1 show that most of the autistic children in 
both the atypical autism group (70%) and the childhood 
autism group (75%) are males versus the control 
group (50%) and the females are more likely to have 
Table 1: Demographic data of the atypical autism group, 
childhood autism group, and the control groups
Description Control  
No. 30
Atypical autism 
No. 30
Childhood autism 
No. 60
n % n % n %
Male 15 50 21 70 45 75
Female 15 50 9 30 15 25
Early onset - - 15 50 37 61.7
Regressed onset - - 15 50 23 38.3
Family history - - 16 53.3 27 45
Autism - - 6 20 8 13.3
Mental disord. - - 7 23.3 15 25
Both - - 3 10 4 6.7
Disruptive behav. 5 16.7 29 96.7 60 100
Hyperactivity 4 13.3 24 80 48 80
Impulsivity 6 20 24 80 52 86.7
Temper tantrum - - 12 40 37 61.7
Self-injurious - - 6 20 27 45
Aggressiveness - - - - 7 11.7
GIT problems 6 20 24 80 52 86.7
Sleep problems 4 13.3 11 36.7 42 70
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atypical autism (30%) than childhood autism (25%). 
Early onset of autism is more common in childhood 
autism group (61.7%) versus the atypical autism group 
(50%). However, regressed onset is more prevalent 
in atypical autism group (50%) than childhood autism 
group (38.3%). Family history of mental disorders is 
more common in atypical autism group (53.3%) versus 
the childhood autism group (45%). The disruptive 
behaviors are almost equally common in both atypical 
autism group (96.7%) and childhood autism group 
(100%) relative to control group (16.7%). Likewise, the 
GIT problems are slightly prevailing in the childhood 
autism group (86.7%) versus both the atypical autism 
group (80%) and the control group (20%). In contrast, 
the sleep problems are highly common in the childhood 
autism group (86.7%) relative to both atypical autism 
group (36.7%) and the control group (13.3%).
Figure 1: Comparison between atypical autism group and the 
childhood autism groups (mild-moderate autism and severe autism) 
and control group according to their scores of psychological tests
The findings in Figure 1 show a highly 
significant increase regarding to CARS scores in the 
severe autism group, the mild-moderate autism group, 
and the atypical autism group (p < 0.0001) compared 
to the control group. Meanwhile, highly significant 
decrease regarding to Vineland scores is recorded in the 
severe autism group, the mild-moderate autism group 
and the atypical autism group (P<0.0001) versus the 
control group. Furthermore, the results show a highly 
Figure 2: Classification of  the autism groups according to Vineland 
scores
significant difference regarding CARS and Vineland 
scores between the severe autism group and both the 
atypical autism and the mild-moderate autism groups 
(p < 0.0001).
The results in Figure 2 show that 16 children 
in the atypical autism group (53.3%) have Vineland 
scores of mild deficient IO, 4 children (13.3%) have 
scores of moderate deficient IQ, 7 children (23.3%) 
have scores of borderline IQ, 2 children (6.66%) have a 
low average IQ, and 1 child (3.33%) has an average IQ, 
with no scores in severe deficient IQ. While in the mild-
moderate autism group, 9 children (30%) have scores 
of mild deficient IQ, 12 children (40%) have scores of 
moderate deficient IQ, 4 children (13.3%) have scores 
of severe deficient IQ, 3 children (10%) have borderline 
IQ, 1 child (3.33%) has scores of low average IQ, and 
1 child (3.33%) has scores of average IQ. In the severe 
autism group, 2 children (6.66) have a mild deficient IQ, 
14 children (46.7) have a moderate deficient IQ, and 
14 children (46.7%) have a severe deficient IQ with no 
borderline or low average and average IQ. In the control 
group, 3 children (10%) have scores of borderline IQ, 
18 children (60%) have scores of low average IQ, and 9 
children (30%) have scores of average IQ.
The records in Figure 3a show a highly 
significant increase in GABA plasma levels comparing 
the atypical autism group to the control group (p 
= 0.005). However, there is a significant increase in 
GABA plasma levels in the mild-moderate autism group 
relative to the atypical autism group (p = 0.049). There 
is also a greatly significant increase in GABA plasma 
levels comparing the severe autism group to both the 
mild-moderate and the atypical (p < 0.0001). Regarding 
the BDNF serum levels (Figure 3b), there is a significant 
Figure 3: Comparison between atypical autism group, childhood 
autism groups (mild-moderate autism and severe autism groups), 
and the control group regarding the biochemical measurements; 
gamma-aminobutaric acid (a), brain-derived neurotrophic factor (b), 
serotonin (c), and dopamine (d)
dc
ba
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increase (p = 0.02) in comparing atypical autism group 
with the control group. In contrast, there is no significant 
change in BDNF serum levels between mild-moderate 
autism group and the atypical autism group (p = 0.442). 
A highly significant increase in serum BDNF is registered 
in comparing the severe autism group with the atypical 
autism group (p < 0.0001) and only a significant increase 
comparing the severe autism group with to the mild-
moderate autism group (p = 0.02). Data in Figure 3c 
show that there is a highly significant increase regarding 
serotonin plasma levels in comparing the atypical autism 
group with the control group (p < 0.0001). The results 
in Figure 3d show a highly significant increase in DA 
plasma levels in the atypical autism group versus the 
control (p < 0.0001). Meanwhile, there is no significant 
difference in comparing all the autism groups with each 
other as regard serotonin plasma levels (Figure 3c). As 
regard DA plasma levels, there is a highly significant 
increase in the mild-moderate autism group relative to the 
atypical autism group (p = 0.005) and also in the severe 
autism when compared with both the atypical and the 
mild-moderate autism groups (p < 0.0001) (Figure 3d).
The records in Figure 4 constitute the 
Pearson’s correlation between the CARS test and 
Vineland test in childhood autism group. The data show 
a highly significant negative correlation between CARS 
and Vineland scores r = −0.568 (Figure 4a) and a highly 
significant positive correlation between CARS scores 
and both GABA r = 0.387 (Figure 4b) and DA r = 0.657 
(Figure 4c). The results also show a highly significant 
negative correlation between Vineland scores and DA 
r = −0.452 (Figure 4d).
The results in Figure 5 indicate the Pearson’s 
correlation between the measured biochemical 
parameters with each other in childhood autism 
group. The data show a significant positive correlation 
between DA and both GABA r = 0.303 (Figure 5a) and 
BDNF r = 0.327 (Figure 5b). However, there is a highly 
significant positive correlation between GABA and 
BDNF levels r = 0.387 (Figure 5c).
Discussion
In the current study, 33.3% of the autistic 
children are diagnosed as atypical autism and 66.7% are 
diagnosed with childhood autism. This is in conformity 
with Hussein et al. [18] who reported that typical autism 
is more common than atypical autism in both Saudi and 
Egyptian groups. Furthermore, the preponderance of 
autistic patients in both atypical autism and childhood 
autism groups is boys 70% and 75%, respectively. This 
is in keeping with Xiong et al. [19] who reported a higher 
predominance of boys over girls in association with 
autistic children.
This study demonstrated that 50% of atypical 
autism and 38.3% of childhood autism had regressed 
onset. This is concurrent with Hansen [20] study which 
recorded regression in 41% of subjects with autism; 
26% lost either language or social skills; while 15% lost 
both. The present data showed that 53.3% of atypical 
autism and 45% of childhood autism have a family 
history of autism, other mental disorders, or both. This 
comes in line with that of Sandin et al. [21] who stated 
that heritability of ASD and autistic disorder is evaluated 
to be approximately 50%. Most of the autistic children 
in this study had disruptive behaviors, 96.7% in atypical 
autism and 100% in childhood autism versus 16.7% 
in the control group. The most frequent disruptive 
behaviors in the atypical autism and the childhood 
autism groups, respectively, were hyperactive (80%) 
Figure 4: Pearson’s correlation between the Childhood Autism Rating 
Scale  (CARS)  test  and Vineland  test  (a), CARS  test  and  gamma-
aminobutaric acid (b), CARS test and dopamine (DA) (c), and 
Vineland test and DA (d) in childhood autism group
dc
ba
Figure 5: Pearson’s correlation between the measured biochemical 
markers, dopamine (DA) and gamma-aminobutaric acid (GABA) (a), 
DA and brain-derived neurotrophic factor (BDNF) (b), and GABA and 
BDNF (c) in childhood autism group
c
a
b
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in both groups, impulsivity (80%), (86.7%), temper 
tantrum (40%), (61.7%), self-injurious (20%), (45%), 
and aggressiveness (0%), (11.7%), respectively. These 
results are in harmony with those of Kats et al. [22] 
who mentioned that disruptive behaviors frequently 
manifest themselves in children with ASD and up to 
60% of subjects with autism and an intellectual disability 
present with difficult-to-manage behaviors, including 
self-injurious, disruptive, and destructive behaviors. 
Furthermore, most of the autistic children in the present 
study had gastrointestinal (GI) problems; 80% in 
atypical autism and 86.7% in childhood autism versus 
20% in the control group. These findings are paralleled 
to the recent report by Lefter et al. [23] who stated 
that the increased prevalence of GI symptoms in ASD 
patients indicating that GI dysfunctions are of particular 
relevance in ASD. These various GI manifestations are 
related to the autonomous nervous system affecting the 
parasympathetic tone and stress responsiveness as 
well as abnormal dynamics of neurohormones such as 
serotonin or GABA. Research based on parental note 
recommends that autistic children are more liable to have 
sleep problems than children with other developmental 
disorders and children with no developmental 
diagnosis [24]. This finding is in accordance with the 
results of the present study which demonstrated that 
36.7% of atypical autism and 70% of childhood autism 
versus 13.3% of the control group had sleep problems.
In the present investigation, measuring 
the autism severity was done using CARS which 
demonstrated that in the atypical autism group, 100% 
had autistic features, while in the childhood autism 
group, 50% had mild-moderate autism and the rest 
50% had severe autism. These results match the 
previous researches indicating that CARS total score 
changes significantly between the two groups, with 
autistic disorder being significantly elevated than 
atypical autism [25]. Results of the present study echo 
those of the previous findings indicating that the CARS 
total score changes significantly by diagnostic group, 
as a significantly higher total CARS scores have been 
found in the severe autism group versus the mild-
moderate autism group when compared both with 
the atypical autism group and the control group. The 
clinical significant differences reported in CARS total 
scores among the diagnostic groups are congruent 
with the results of Chlebowski et al. [26] who supported 
the utilization of CARS as a stable measure of autism 
severity.
The current results also showed that there are 
significantly lower scores in Vineland Adaptive Behavior 
Scale with the elevation of the disease severity. Greatly 
significant (p < 0.0001) low scores have been detected 
by comparing the severe autism group with the mild-
moderate autism group and in comparing both to the 
atypical autism group and the control group. These 
results are in concert with those of Paul et al. [27] who 
commented that individuals with atypical autism scored 
higher than those with autism in Vineland Adaptive 
Behavior Scale. This showed parallelism with our 
results, as it has been detected a significant (p < 0.0001) 
negative correlation between CARS and Vineland IQ in 
childhood autism group.
The present study showed an increase of 
GABA plasma level with the increase in the severity of 
the disease. It has been observed a marked significant 
increase (p < 0.0001) in the plasma level of GABA 
in comparing both the mild-moderate autism and the 
severe autism groups to both the atypical autism group 
and the control group and in comparing the severe to 
the mild-moderate autism groups. Furthermore, it has 
been found a marked significant (p = 0.002) positive 
correlation between GABA levels and CARS scores 
in the childhood autism group. These results are 
comparable to those in the previous study done by 
Enticott et al. [28] which demonstrated the significantly 
elevated level of plasma GABA in patients with autism 
in comparison to the controls. These investigators 
stated that GABA, as the major inhibitory transmitter in 
the CNS, has been implicated in the pathophysiology of 
ASDs. As well, Mendez et al. [29] proved the correlation 
between elevated plasma GABA and severity of 
autism using CARS and that severe autistics show 
higher plasma GABA levels relative to mild-moderate 
patients. There are many evidences supporting the 
function of GABA in the etiology or pathophysiology of 
autistic disorders. One influential theory proposed by 
Casanova et al. [30] is that inhibitory GABA signaling 
inside and among cortical minicolumns are altered due 
to the decreasing in the neuropil which divides closest 
minicolumns leading to information processing that 
tends to demonstrate stronger than normal inequity 
between connected stimuli rather than generalization 
between them. This may suggest why patients with 
autism demonstrate a preference for precise similarity 
(e.g., the same daily routines, the same behaviors, and 
interests), as just precisely the identical stimuli would 
be detected as similar. It may also clarify sensory 
hypersensitivities and the occasional existence of 
superior “savant” abilities in a narrow domain.
The tabulated results pointed to the heightened 
of BDNF level with the increase in the severity of the 
disease, as it has been found a marked significant 
increase (p = 0.002) in BDNF serum level in severe 
autism group comparative to the atypical autism 
group and a significant increase (p = 0.02) in its level 
in comparison to the mild-moderate autism group. In 
addition, an insignificant increase (p = 0.4) in BDNF 
serum level is recorded in comparing the mild-moderate 
autism group to the atypical autism group. These results 
are consistent with the study of Zhang et al. [31] which 
measured serum level of BDNF in Chinese patients 
with ASD, and the severity of ASD was evaluated with 
CARS score. Their results suggested that the median 
serum BDNF levels are significantly (p < 0.0001) higher 
in autistic children as compared to normal cases, and 
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they discovered that its higher levels may be considered 
as an independent risk factor of ASD. Wang et al. [32] 
also detected that the mean serum BDNF levels are 
significantly (p < 0.0001) upregulated in children with 
ASD in comparison to the control cases and serum 
BDNF levels may be correlated independently with the 
severity of ASD. BDNF can influence synaptic inhibition 
by reducing the surface constancy and expression 
of GABA type A [33]. Powers et al. [34] observed that 
BDNF exposure reduces the inhibitory effects of GABA 
on parvocellular neuroendocrine neurones from the 
paraventricular nucleus of the hypothalamus and 
that oral administration of the amino acid/inhibitory 
neurotransmitter GABA reportedly increases the resting 
serum growth hormone (GH) concentrations by 400%. 
One of the mechanisms mediating BDNF is the GH. The 
role of BDNF in the pathophysiology of ASD was defined 
by Almeida et al. [35] who stated that activating BDNF 
signaling can sometimes be pathogenic. For example, 
adult transgenic mice overexpressing BDNF are prone 
to seizures and increasing of BDNF levels enhances 
pain sensitivity. Moreover, during early embryonic brain 
development, the cell cycle parameters of proliferating 
neuroblasts and the laminar fate of their progeny are 
extremely sensitive to either increased or decreased 
BDNF signaling. These explanations greatly support 
the present study, which showed a highly significant 
(p = 0.002) positive correlation between BDNF and 
GABA level in the childhood autism group, which both 
their levels are increased with the severity of the disease.
In this study, plasma level of serotonin was found 
to be highly significantly elevated in comparing all the 
autistic groups versus the control group, but insignificant 
change of its level has been detected by comparing all 
the autistic groups with each other. These results fit 
similar findings recorded by Chandana et al. [36] who 
found a high proportion of children with autism exhibiting 
elevated plasma serotonin levels and specific alterations 
in serotonin biosynthesis. The observed increase of 
serotonin plasma level in all autistic groups under study 
could be referred to the increased of BDNF observed in 
these patients, as BDNF has also been found to regulate 
serotonergic neurotransmission in vitro. In addition, 
BDNF administration has been revealed to increase the 
synthesis of serotonin in vivo [37]. Thereby, serotonin 
has a potential role in the pathogenesis of autism. In 
addition, blood serotonin levels have been discovered 
to correlate inversely with verbal IQ and to correlate 
positively with the severity of autism [38].
In the current approach, plasma concentration 
of DA showed insignificant (p = 0.2) increase in the 
atypical autism group relative to the healthy control group, 
while it showed significant increase with the severity of 
the disease, as it showed highly significant increase in 
both the mild-moderate (p = 005) and the severe autism 
groups (p < 0.0001) in respect to the atypical autism 
group and also in comparing the severe autism group 
to the mild-moderate autism group. These results are 
in accordance with those of El-Ansary et al. [39] who 
reported that Saudi autistic patients have a significantly 
higher level of DA compared to healthy subjects. One 
explanation for the significant elevation of DA and 
increased its level in correlation with the severity of the 
disease may be due to BDNF, which induces long-term 
changes in brain function by influencing the reactions 
of its target neurons to DA [40]. Hence, dysregulation 
of the function of BDNF coupled with dysfunction of DA, 
a neurotransmitter that is critical for so many cognitive 
and motor skills may underlie the expression of specific 
symptoms connected with autism. It is well documented 
that the dopaminergic system has been correlated with 
speech and communication abilities which are defective 
in autism. DA also modulates and reduces behavioral 
reactions to changes in the social environment [41]. 
This is in consistent with the current results as it has 
been found a significant positive correlation (p = 0.01) 
between DA and both BDNF and GABA, and a highly 
significant (p = 0.002) positive correlation between DA 
levels and CARS scores in the childhood autism group, 
which all are increased with the severity of the disease.
Study limitations
This study has some potential limitations; 
the sample size was relatively small because it was 
so difficult to find children not taking any medications 
for at least 1 month as in our exclusion criteria since 
any neurological or psychiatric drugs will affect the 
neurochemical level that we were measuring. As well, it 
was so difficult to withdraw blood from autistic children 
at this young age from 2 to 7 years as almost all of them 
were having severe behavioral problems as hyperactivity 
and temper tantrums. Moreover, for the clinical work, 
we had some limitations as more phenotypes of autism 
as Asperger disorder should be added in the study 
population to be compared with childhood autism and 
atypical autism groups but Asperger disorder is not a 
common disorder in Egypt.
Conclusion
The data of this study speak for the importance 
of BDNF in the brain where any prolonged perturbations 
in its level due to the increase of GABA most probably 
lead to aberration in serotonin and DA, which are well 
key actors in the pathophysiology of many psychiatric 
diseases in general and ASD in particular. In light of these 
evidences, it should reconsider the crosstalk between 
the brain neurochemicals committed in ASD to set up 
a line of targeted therapy for this neurodevelopmental 
disorder.
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Recommendations
•	 Mapping the neurochemical markers onto 
clinically distinct categories, to better 
understanding the multidimensional and 
complex clinical, cognitive, and behavioral 
phenotype that are connected with autism and 
its overlap with other disorders.
•	 Establishing the reliable biomarkers implicated 
in the pathophysiology of autism to spotlight 
into the complex crosstalk between these 
biomarkers.
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